Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Issue 1 (February 2022)

• Record Type: Journal Article
• Authors: Cil, Ibrahim; Kucukarda, Ahmet; Atcı, Muhammed Mustafa; Secmeler, Saban; Paksoy, Nail; Ferhatoglu, Ferhat; Ak, Naziye; Ayhan, Murat; Tataroglu Ozyukseler, Deniz; Onder, Arif Hakan; Avci, Okan; Oyman, Abdilkerim; Okten, Ilker Nihat; Gulturk, Ilkay; Akagunduz, Baran; Basoglu, Tugba; Cakir, Emre; Hacibekiroglu, Ilhan; Ozcelik, Melike; Aydiner, Adnan
• Is Part Of: Tumori. Volume 108:Issue 1(2022)
• Page Start: 19
• Page End: 25
• Publication Date: 2022-02
• Subjects: HER2 positive -- metastatic breast cancer -- older patients -- real-world; Cancer -- Periodicals; 616.994
• DOI: 10.1177/03008916211037739
• Languages: English
• ISSNs: 0300-8916

Abstract

Introduction: Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate and its survival advantage has been shown in advanced human epidermal growth factor receptor 2 (HER2)–positive breast cancer. However, clinical trials underrepresent patients ⩾65 years of age, leading to a lack of information in this population. We analyzed the real-world outcomes of older women who were treated with T-DM1 therapy. Methods: We performed a multicenter, observational, retrospective analysis of patients aged ⩾65 years treated with T-DM1. A total of 93 patients from 10 cancer centers were involved in the study. Our goal was to determine the survival, response rates, and toxicity profile in T-DM1–treated patients, as well as the factors that influence survival. Results: Median follow-up was 12.2 months. Objective response rate was 29%. Median progression-free survival (PFS) and overall survival (OS) were 8.47 and 15.0 months, respectively. In multivariate analysis, Eastern Cooperative Oncology Group Performance Score 2 was found to be an independent prognostic factor for worse PFS (hazard ratio [HR] 1.81, p = 0.032) and OS (HR 2.33, p = 0.006). Any adverse event (AE) was seen in 92.5% of patients; grade 3 or 4 AEs were seen in 30.1%. Dose reduction or treatment discontinuation rates were 11.8% and 6.5%, respectively. Conclusion: The efficacy of T-DM1 was acceptable and it was generally well-tolerated among older patients with advanced HER2-positive breast cancer.